Verona Pharma (VRNA) Stock Forecast & Price Target

$22.73

+0.58 (+2.62%)

(As of 07/26/2024 ET)

Verona Pharma - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 5 Analyst Ratings

Based on 5 Wall Street analysts who have issued ratings for Verona Pharma in the last 12 months, the stock has a consensus rating of "Buy." Out of the 5 analysts, 5 have given a buy rating for VRNA.

Consensus Price Target

$36.00
58.38% Upside

High Forecast	$38.00
Average Forecast	$36.00
Low Forecast	$33.00

According to the 5 analysts' twelve-month price targets for Verona Pharma, the average price target is $36.00. The highest price target for VRNA is $38.00, while the lowest price target for VRNA is $33.00. The average price target represents a forecasted upside of 58.38% from the current price of $22.73.

Type	Current Forecast 7/27/23 to 7/26/24	1 Month Ago 6/27/23 to 6/26/24	3 Months Ago 4/28/23 to 4/27/24	1 Year Ago 7/27/22 to 7/27/23
Consensus Rating	Buy	Buy	Buy	Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	4 Buy rating(s)	4 Buy rating(s)	6 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$36.00	$33.50	$33.60	$30.00
Forecasted Upside	58.38% Upside	99.02% Upside	86.89% Upside	107.46% Upside

Get Verona Pharma Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter.

Ad Monument Traders Alliance

This student turned $1,300 into $45,000 in just 4 Months!

With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... In fact, it just detected a move happening this MONDAY.

See here to see the full details.

VRNA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

VRNA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Verona Pharma Stock vs. The Competition

Type	Verona Pharma	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.72	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	58.38% Upside	3,123.46% Upside	9.17% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
7/22/2024	Canaccord Genuity Group 1 of 5 stars	Boost Target	Buy ➝ Buy	$35.00 ➝ $37.00	+61.22%
6/28/2024	Truist Financial 1 of 5 stars	Boost Target	Buy ➝ Buy	$32.00 ➝ $38.00	+157.10%
6/27/2024	HC Wainwright 3 of 5 stars	Boost Target	Buy ➝ Buy	$32.00 ➝ $36.00	+145.06%
4/16/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$31.00 ➝ $36.00	+127.85%
3/1/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$33.00	+91.64%
6/28/2023	500.com Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Reiterates
Get the Latest News and Ratings for VRNA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Verona Pharma and its competitors with MarketBeat's FREE daily newsletter.
3/20/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target		$26.00 ➝ $31.00	+66.67%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 10:01 PM ET.

VRNA Forecast - Frequently Asked Questions

What is Verona Pharma's forecast for 2024?: According to the research reports of 5 Wall Street equities research analysts, the average twelve-month stock price forecast for Verona Pharma is $36.00, with a high forecast of $38.00 and a low forecast of $33.00.
Should I buy or sell Verona Pharma stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VRNA shares.
Does Verona Pharma's stock price have much upside?: According to analysts, Verona Pharma's stock has a predicted upside of 110.67% based on their 12-month stock forecasts.
What analysts cover Verona Pharma?: Verona Pharma has been rated by research analysts at Canaccord Genuity Group, HC Wainwright, and Truist Financial in the past 90 days.
Do Wall Street analysts like Verona Pharma more than its competitors?: Analysts like Verona Pharma more than other "medical" companies. The consensus rating for Verona Pharma is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how VRNA compares to other companies.